Your Location：
Home >
Browse articles >
AKR1C3 as a therapeutic target to overcome erlotinib resistance in lung adenocarcinoma
AKR1C3 as a therapeutic target to overcome erlotinib resistance in lung adenocarcinoma
- “In the field of xxx, expert xx has made significant research progress. By establishing the xx system/exploring the xx topic/verifying the xx conjecture, they have provided solutions to address xx problems/open up a new direction for xx research/lay a foundation for the construction of the xx system.”
- Military Medical Research Vol. 12, Issue 10, Pages: 1667-1669(2025)
DOI： 10.1186/s40779-025-00593-4
Accepted：13 January 2025
Scan QR Code
AI Introduction
Full Text(HTML)
Figs( 1 ) Tabs( 0 )
References
Publication Info
Metrics
106
Views
43
Downloads
0
CSCD
Alert me when the article has been cited
Submit
Tools
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Related Articles
Endothelial barrier and sepsis: mechanisms and potential therapeutic strategies
Engineered exosomes for diabetic foot ulcers: lessons learned, challenges remain
Frostbite: diagnosis, treatment, prognosis, and future directions
Engineering of functional auditory neurons from human induced pluripotent stem cells
Bridging the lung cancer screening eligibility gap: evaluation of guideline applicability in asymptomatic patients
Related Author
William C. Cho
Related Institution
No data
